Restricted accessEditorialFirst published online 2022-2
Major Adverse Cardiovascular Events According to Thrombolysis in Myocardial Infarction Flow Grade and Intervention Timing Before Percutaneous Coronary Intervention in Non–ST-Segment Elevation Myocardial Infarction
PuymiratESimonTCaylaG, et al.Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the fast-mi program (french registry of acute st-elevation or non-st-elevation myocardial infarction) 1995 to 2015. Circulation2017; 136(20): 1908–1919.
2.
ChanMYSunJLNewbyLK, et al.Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction. Circulation2009; 119(24): 3110–3117.
3.
SongYBHahnJYKimJH, et al.Comparison of angiographic and other findings and mortality in non-ST-segment elevation versus ST-segment elevation myocardial infarction in patients undergoing early invasive intervention. Am J Cardiol2010; 106(10): 1397–1403.
4.
KimYHHerAYJeongMH, et al.Two-year clinical outcomes according to pre-pci timi flow grade and reperfusion timing in non-stemi after newer-generation drug-eluting stents implantation. Angiology2021; DOI: 10.1177/00033197211012537.
5.
ZeymerUHuberKFuY, et al.Impact of TIMI 3 patency before primary percutaneous coronary intervention for ST-elevation myocardial infarction on clinical outcome: results from the ASSENT-4 PCI study. Eur Heart J Acute Cardiovasc Care2012; 1(2): 136–142.
6.
De LucaGBrenerSJMehranR, et al.Implications of pre-procedural TIMI flow in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary revascularization: insights from the ACUITY trial. Int J Cardiol2013; 167(3): 727–732.
7.
ZhangYGaoCLiuH, et al.Routine early versus deferred provisional tirofiban treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Clin Exp Pharmacol Physiol2013; 40(4): 289–294.
8.
LemesleGLaineMPankertM, et al.Optimal timing of intervention in nste-acs without pre-treatment: the early randomized trial. JACC Cardiovasc Interv2020; 13(8): 907–917.
9.
CaseBCYerasiCWangY, et al.Admissions rate and timing of revascularization in the united states in patients with non-st-elevation myocardial infarction. Am J Cardiol2020; 134: 24–31.
10.
AroraSMatsushitaKQamarAStaceyRBCaugheyMC. Early versus late percutaneous revascularization in patients hospitalized with non ST-segment elevation myocardial infarction: the atherosclerosis risk in communities surveillance study. Catheter Cardiovasc Interv2018; 91(2): 253–259.
11.
SimDSJeongMHAhnY, et al.Clinical impact of immediate invasive strategy in patients with non-ST-segment elevation myocardial infarction. Int J Cardiol2016; 221: 937–943.
12.
JobsAMehtaSRMontalescotG, et al.Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials. Lancet2017; 390(10096): 737–746.
13.
D’AscenzoFBiondi-ZoccaiGMorettiC, et al.TIMI, GRACE and alternative risk scores in acute coronary syndromes: a meta-analysis of 40 derivation studies on 216,552 patients and of 42 validation studies on 31,625 patients. Contemp Clin Trials2012; 33(3): 507–514.
14.
BailleulCAissaouiNCaylaG, et al.Prognostic impact of prepercutaneous coronary intervention TIMI flow in patients with ST-segment and non-ST-segment elevation myocardial infarction: results from the FAST-MI 2010 registry. Arch Cardiovasc Dis2018; 111(2): 101–108.
15.
JoostAStiermaierTEitelC, et al.Impact of initial culprit vessel flow on infarct size, microvascular obstruction, and myocardial salvage in acute reperfused st-elevation myocardial infarction. Am J Cardiol2016; 118(9): 1316–1322.
16.
SchaafMJMewtonNRioufolG, et al.Pre-PCI angiographic TIMI flow in the culprit coronary artery influences infarct size and microvascular obstruction in STEMI patients. J Cardiol2016; 67(3): 248–253.
